▼ 1.05%
prev close
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-02-16 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1188d ago | — | |
| 2022-11-01 | TAKTakeda Pharmaceutical Company Limited American Depositary Shares | Buy | $1,001 - $15,000 | 1275d ago | — |
2023-02-16
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1188d ago
2022-11-01
Virginia Foxx
TAK
Amount
$1,001 - $15,000
Filed
1275d ago
Recent News
Powered by Polygon.io
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035
Jury Hits Takeda With $885 Million Antitrust Verdict
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
Trade Timeline
Congressional activity, newest first
Virginia Foxx
2023-02-16 · Purchase
$1,001 - $15,000
Virginia Foxx
2022-11-01 · Purchase
$1,001 - $15,000